GlassScriptPhysician profile
Marc A Tribble
NPI 1982669883
$693,377.69
in general payments reported to CMS, 2019-2025
39 companies · $105K in 2025
The $105K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118K · 2020: $46K · 2021: $62K · 2022: $104K · 2023: $122K · 2024: $137K · 2025: $105K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $287K · Travel and Lodging: $48K · Food and Beverage: $19K · Honoraria: $6,085 · Consulting Fee: $4,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $286,565.00 |
| Travel and Lodging | $48,211.54 |
| Food and Beverage | $18,647.77 |
| Honoraria | $6,085.00 |
| Consulting Fee | $4,560.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $531,486.60 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $113,355.21 | 2019-2025 | Epclusa, Biktarvy, Yeztugo |
| Janssen Products, LP | $33,414.80 | 2019-2022 | |
| Theratechnologies INC. | $7,205.57 | 2019-2025 | Egrifta, Trogarzo |
| Merck Sharp & Dohme LLC | $2,130.50 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Janssen Biotech, INC. | $1,283.70 | 2019-2023 | Symtuza |
| Glaxosmithkline, LLC. | $693.02 | 2019-2025 | Arexvy, Shingrix, Menveo |
| Abbvie INC. | $604.95 | 2021-2025 | Vraylar, Mavyret |
| Novo Nordisk INC | $539.76 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Napo Pharmaceuticals INC | $454.21 | 2019-2025 | Mytesi |
| Emd Serono, INC. | $381.37 | 2020-2025 | |
| Lilly USA, LLC | $267.97 | 2022-2025 | Zepbound, Mounjaro, Trulicity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $201.89 | 2023-2025 | Caplyta |
| Antares Pharma, INC. | $181.87 | 2020-2025 | Xyosted, Tlando, Nocdurna |
| Pfizer INC. | $169.37 | 2019-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Tribble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.